pre-IPO PHARMA

noden-pharma PRESS RELEASE ARCHIVE

Sep 9, 2020

PDL BioPharma Completes Divestiture of the Noden Pharmaceutical Business to Stanley Capital


Jul 30, 2020

PDL BioPharma Enters Into Agreement for the Divestiture of the Noden Pharmaceutical Business to Stanley Capital


Nov 15, 2017

Noden Pharma Announces FDA Approval of Tekturna(aliskiren) Oral Pellets for the Treatment of Hypertension in Adults and Children 6 Years of Age and Older


Jun 5, 2017

Noden Pharma Notified of ANDA Filing for Tekturna


Google Analytics Alternative